Replies to post #164643 on Biotech Values

[jellybean]

The Jun 2013 NEJM publication for Ibrutinib reports an ORR of 71% in relapsed/refractory CLL patients. For the N=85 patients that included 2 CR and 58 PR. Those are the most reliable numbers to date for Ibrutinib.